Success Story: Aagami secures funding for US client developing First-in-Class Non-Opioid Analgesic for Pain Relief
We are pleased to announce that Aagami has secured funding for its Milwaukee based client who are developing a Novel First-in-Class NCE for Pain Relief.
This development will help client in advancing its First-in-Class Non-Opioid Analgesic asset to next milestones.
The first-to-market/best-in-class drug platform provides better outcomes for patients suffering from chronic or acute pain.
Highlights include:
- A unique first-to-market & best-in-class solution for a rapidly growing patient population
- Extensive clinical validation, extremely favourable analgesic efficacy and side effect profile. Clear Clinical Data and Benefit.
- Poised to disrupt the pain therapy market, CMX-020 has blockbuster sales potential (addressing a $170+ Billion market).
- Eliminate opioid side effects such as respiratory depression, addiction, constipation, dizziness, fatigue, and vertigo: the first opioid-equivalent drug without opioid side effect-risk.
- Multi-modal MOA producing analgesia through 7 receptors.
- Gold Standard Therapeutic for Pain Relief
- Strong IP Estate & Related Barriers-to-Entry
- Clear Pathway forward with FDA
Next milestones
- Perform few studies, complete three proof of concept (POC) Phase 1-2A studies – Bunionectomy, Dental pain, Oral Diabetic Neuropathy(DPN)
Aagami will continue to support client for further funding and partnering needs.